

Cover Story
FreeGuest Editorial
By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Cancer History ProjectFree
By Alexandria Carolan and Katie Goldberg
Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?
- MSK’s AML researcher Bayard “Barney” Clarkson, former president of ASCO and AACR, dies at 99
- NIH agrees to review hundreds of denied or shelved grant applications
- Patient advocate David Mitchell, 75, dies of multiple myeloma
- Paul Engstrom, Fox Chase pioneer of cancer prevention, dies at 89













